Otsuka Pharmaceutical Acquired IBio's Assets Related To Its Early-stage Programmed Cell Death Protein 1 Agonist Program; IBio Will Receive An Upfront Payment Of $1M And Is Eligible To Receive Additional Contingent Cash Payments Of Up To $52.5M
Otsuka Pharmaceutical Acquired IBio's Assets Related To Its Early-stage Programmed Cell Death Protein 1 Agonist Program; IBio Will Receive An Upfront Payment Of $1M And Is Eligible To Receive Additional Contingent Cash Payments Of Up To $52.5M
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.